AAM Perspective on Drug Pricing Conference of Western Attorneys - PowerPoint PPT Presentation

May 12, 2023 •289 likes •390 views

AAM Perspective on Drug Pricing Conference of Western Attorneys General January 9, 2018 Three Facts That Reveal Significant Difference Between the Generic & Brand Business Models Generics fill 89% of all prescriptions for FACT 1 only

AAM Perspective on Drug Pricing Conference of Western Attorneys General January 9, 2018
Three Facts That Reveal Significant Difference Between the Generic & Brand Business Models… Generics fill 89% of all prescriptions for FACT 1 only 26% of the total prescription spend. Generic drug pricing is deflationary. FACT 2 The supply chain has a greater impact FACT 3 on generic pricing than do drug manufacturers. 2
Fact 1: 89% of Prescriptions for 26% of Cost PAGE 3
Fact 2: Generic Market is Deflationary PAGE 4
Generic Price Deflation in the Marketplace 5
Fact 3: Supply Chain has Profound Impact on Generic Prices PAGE 6
Sustainable Generic Competition is Threatened Anticompetitive Abuses Policy Market Consolidation Failures 7
EVERFI Learning Portal 8
Thank You

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

PERSPECTVES ON DRUG PRICING: Is Value - Based Pricing the Answer? Uwe Reinhardt Princeton

PERSPECTVES ON DRUG PRICING: Is Value - Based Pricing the Answer? Uwe Reinhardt Princeton University COUNCIL ON HEALTH CARE ECONOMICS AND POLICY 23 RD PRINCETON CONFERENCE Princeton, New Jersey May 25, 2016 I. VALUE CREATION IN MODERN

834 views • 36 slides

Unwrapping the drug pricing mystery & understanding solutions Sean Dickson NASTAD with Tim

Unwrapping the drug pricing mystery & understanding solutions Sean Dickson NASTAD with Tim Horn Treatment Action Group on behalf of the 1 Fair Pricing Coalition Tackling Drug Costs: A 100 Day Roadmap Webinar Instructions All

465 views • 42 slides

3 The African Perspective on Drug Abuse . International Workshop on Drug Demand Reduction

3 The African Perspective on Drug Abuse . International Workshop on Drug Demand Reduction Campinas, Brazil, December 7-9, 2016 Jane Marie Ongolo Drug Control Coordinator African Union Commission (AUC) Addis Ababa, Ethiopia 1 AFRICAN

1k views • 25 slides

Endorsing Good Practice Harpreet Chana Head of Pricing PSNC Head of Pricing role involves:

Prescription Pricing Errors and Endorsing Good Practice Harpreet Chana Head of Pricing PSNC Head of Pricing role involves: Negotiating changes to the Drug Tariff with the Department of Health Lead for prescription pricing accuracy

472 views • 33 slides

OIG Work Involving Prescription Drug Pricing and Payments Pricing and Payments Stephanie Yeager

OIG Work Involving Prescription Drug Pricing and Payments Pricing and Payments Stephanie Yeager Office of Evaluation and Inspections Office of Evaluation and Inspections Office of Inspector General Overview Overview OIG Mission and

408 views • 38 slides

Pricing Climate Risk: An Insurance Perspective Howard Kunreuther kunreuther@wharton.upenn.edu

Pricing Climate Risk: An Insurance Perspective Howard Kunreuther kunreuther@wharton.upenn.edu Wharton School University of Pennsylvania Pricing Climate Risk: Refocusing the Climate Policy Debate Tempe, Arizona April 12-13, 2013 80 Total

437 views • 23 slides

Drug Discovery A Regulatory Toxicologists Perspective Anne Field Toxicology Section,

Drug Discovery A Regulatory Toxicologists Perspective Anne Field Toxicology Section, Scientific Evaluation Branch Medicines Regulation Division Australian Cardiovascular Alliance Drug Discovery & Translation Flagship Workshop and

554 views • 22 slides

FDA hearing on Hatch-Waxman Act and drug pricing James Love Knowledge Ecology International

FDA hearing on Hatch-Waxman Act and drug pricing James Love Knowledge Ecology International July 18, 2017 http://keionline.org 1 Transparency 1 Evidence is lacking in important areas, including evidence used to measure and evaluate the

507 views • 12 slides

A Brief History of Drug Pricing Tony Barrueta Senior Vice President, Government Relations

A Brief History of Drug Pricing Tony Barrueta Senior Vice President, Government Relations Partnership for Quality Care May 15, 2015 How a Market is Supposed to Work Sellers sell for as much as they can, leveraging their market power

581 views • 15 slides

Implications of Speaker Pelosis Drug Pricing Plan October 10, 2019 We See Amazing Science, But

Implications of Speaker Pelosis Drug Pricing Plan October 10, 2019 We See Amazing Science, But Its Overlooked in Washington Exciting Advancements in But Washington Is Considering Policies Biopharmaceutical Labs Across the U.S. That Would

569 views • 25 slides

340B Drug Pricing Program Proposed Mega-Guidance Review Compliance Update Region 1 HFMA May 25,

340B Drug Pricing Program Proposed Mega-Guidance Review Compliance Update Region 1 HFMA May 25, 2016 Gary Rosenberg Jeff Norman Verrill Dana, LLP Southwest Consulting Associates Discussion Outline Background 340B Health Survey

849 views • 52 slides

EU regulatory perspective on the potential use of biomarkers in AD drug development Valentina

EU regulatory perspective on the potential use of biomarkers in AD drug development Valentina Mantua, M.D. PhD EMA Workshop on Alzheimers Disease London, 24- 25 November 2014 Public Declaration of transparency/interests* More than 2 More

676 views • 15 slides

The International Pricing Drew McCormick Index Model: Steven Schnelle Breaking Down CMSs

Emily Cook John Warren The International Pricing Drew McCormick Index Model: Steven Schnelle Breaking Down CMSs Proposed Drug Pricing Model November 19, 2018 Overview + Background + The International Pricing Index (IPI) Model +

253 views • 24 slides

Containing Marijuana: An FDA Perspective Stephen Ostroff, M.D. Food and Drug Administration

Medical Products Containing Marijuana: An FDA Perspective Stephen Ostroff, M.D. Food and Drug Administration (FDA) Smart Approaches to Marijuana (SAM) Atlanta, GA March 31, 2015 2 Disclosure Statement I have no financial relationships

788 views • 39 slides

Antibacterial Drug Development an FDA Perspective Ed Cox, MD MPH Director, Office of

Antibacterial Drug Development an FDA Perspective Ed Cox, MD MPH Director, Office of Antimicrobial Products OND/CDER/FDA 1 1 Background Development of new antibacterial agents is essential to meet patient needs Need therapies to

104 views • 8 slides

This Session Implicit Price Discrimination (continued) 1. Implicit Price Discrimination 2. Airline

Road Map for Prices and Markets: Pricing under Different Market Structures Monopoly Pricing Pricing by a monopolist (e.g., Microsoft) Some pricing fallacies Not all gains from trade realized or extracted What we did so far: Pricing

339 views • 20 slides

Division of Workers Compensation Public Meeting September 8, 2015 Issues Related to

State of California Edmund G. Brown Jr. Governor Division of Workers Compensation Public Meeting September 8, 2015 Issues Related to Developing an Evidence- Based Drug Formulary for Use in the California Workers' Compensation System 1

377 views • 18 slides

Adverse Drug Tiering Practices in the United States Michaela Jackson, MS Public Health

Adverse Drug Tiering Practices in the United States Michaela Jackson, MS Public Health Program and Outreach Coordinator Hepatitis B in the U.S. Disproportionately impacts Asian Americans, Pacific Islanders, and African Immigrants

464 views • 20 slides

Counterfeit Medicine In America: 2020 The partnership is a coalition of over 40 healthcare,

Counterfeit Medicine In America: 2020 The partnership is a coalition of over 40 healthcare, manufacturer, and patient organizations dedicated to fighting counterfeit medicines. Shabbir Imber Safdar Executive Director, PSM

962 views • 59 slides

Medicare Part D Drugs JOHN KAISER NCRO DIRECTOR AND INSURANCE COMMITTEE Not everyone needs a

Medicare Part D Drugs JOHN KAISER NCRO DIRECTOR AND INSURANCE COMMITTEE Not everyone needs a standalone Part D Drug plan but everyone does need Part D Drug coverage. Virtually all Advantage Plans today include a Part D Drug plan but, you

341 views • 21 slides

Price Transparency Program Agenda 1. Overview of Oregons Prescription Drug Price program 2.

Oregon Prescription Drug Price Transparency Program Agenda 1. Overview of Oregons Prescription Drug Price program 2. New drug reporting 3. Annual price increase reporting 4. Information claimed to be trade secret 5. Report timelines 6.

569 views • 36 slides

HATCH-WAXMAN ACT: OVERVIEW What You Really Need To Know and Then Some Richard T. Ruzich 1

HATCH-WAXMAN ACT: OVERVIEW What You Really Need To Know and Then Some Richard T. Ruzich 1 Background of Hatch-Waxman Where Are The Cheap Drugs? Roche Products Inc. v. Bolar Pharmaceutical 733 F.2d 858 (Fed. Cir. 1984)

304 views • 8 slides

Present Health Care Costs: Key Federal and State Strategies Sponsored by a generous grant

Present Health Care Costs: Key Federal and State Strategies Sponsored by a generous grant from the Peter G. Peterson Foundation The Federal Budget and Health Care presented by Robert Bixby, Executive Director THE CONCORD COALITION

887 views • 32 slides

Though pharma growth slides, blockbusters reach new record Michael Rosen Published 06/ 06/ 05

Though pharma growth slides, blockbusters reach new record Michael Rosen Published 06/ 06/ 05 The global pharmaceutical market failed to reach double-digit growth in 2004 for the first time in about nine years. Key reasons for this focused on

296 views • 4 slides